Physicians' Academy for Cardiovascular Education
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

Strengths and limitations of one-month DAPT trial

3' education - Nov. 19, 2020 - Róisín Colleran, MD

Comparing P2Y12 inhibitors in patients undergoing elective PCI

3' education - Nov. 19, 2020 - Jur ten Berg, MD, PhD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

What is the value of a polypill with or without aspirin?

3' education - Nov. 16, 2020 - Prof. Salim Yusuf, MD

Side effects in a trial with statin, placebo and tablet-free periods

3' education - Nov. 16, 2020 - Prof. Darrel Francis, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

No effect of omega-3 fatty acids and vitamine D supplements on incident AF

3' education - Nov. 15, 2020 - Christine Albert, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Benefit with cardiac myosin activator in HFrEF

3' education - Nov. 14, 2020 - Prof. John Teerlink, MD

Detection of widespread atherosclerosis in Swedish population

3' education - Nov. 14, 2020 - Prof. Göran Bergström, MD, PhD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Role of GLP-1RA in practice

*NEW* Subtitling in German, Italian, Spanish, French, and Chinese

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

Increased in-hospital mortality in COVID-19 patients with myocardial injury and echocardiographic abnormalities

Literature - Dec. 1, 2020 - Giustino G, et al. - J Am Coll Cardiol. 2020

A study of 305 hospitalized COVID-19 patients showed that approximately two-third of patients with evidence of myocardial injuries had echocardiographic abnormalities. In these patients, risk of in-hospital mortality was increased.

Lower 1-year LDL-c after revascularization reduces MACCE in T2DM and CHD

Literature - Dec. 1, 2020 - Farkouh ME, et al. - J Am Coll Cardiol 2020

Achievement of lower 1-year LDL-c levels after revascularization procedure reduces long-term major adverse cardiac or cerebrovascular events (MACCE) in patients with T2DM and CHD, particularly in patients undergoing PCI.

How do GLP-1RAs work?

New - subtitling in German, Italian, Spanish, French, and Chinese

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD
Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

No association between myopathy risk score and other muscle symptoms in patients on simvastatin

Literature - Nov. 25, 2020 - Hopewell JC, et al. - Eur Heart J 2020

An observational study showed that the absolute risk of myopathy is low in patients taking simvastatin. A myopathy risk score showed no association with other muscle symptoms in these patients.

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD
Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

Nonsteroidal MRA reduces kidney and CV risks in patients with CKD and T2DM with or without CVD

News - Nov. 24, 2020

AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

PCSK9i reduces complex coronary disease that requires revascularization

News - Nov. 24, 2020

AHA 2020 Evolocumab additionally given to statins in ASCVD patients significantly reduced the risk of developing complex coronary disease that needs revascularization, including complex PCI or CABG.

P2Y12i combined with aspirin superior to aspirin in patients with ipsilateral atherosclerotic stenosis

News - Nov. 24, 2020

AHA 2020 This subanalysis of THALES showed that ticagrelor in combination with aspirin significantly reduced the 30-day risk of stroke or death compared to aspirin in high-risk patients with ipsilateral atherosclerotic stenosis.

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.